PARSIPPANY, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on September 13, 2024 to stockholders of record at the close of business on August 27, 2024.
About embecta
embecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.
| Contacts: | |
| Media Christian Glazar Sr. Director, Corporate Communications 908-821-6922 This email address is being protected from spambots. You need JavaScript enabled to view it. | Investors Pravesh Khandelwal VP, Head of Investor Relations 551-264-6547 This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$20.25 |
| Daily Change: | 0.45 2.27 |
| Daily Volume: | 228,552 |
| Market Cap: | US$1.180B |
September 03, 2024 August 09, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
